Cardiac safety assays

Current Opinion in Pharmacology

Volumn 15, Issue 1, 2014, Pages 16-21

  Heijman, Jordi ^a   Voigt, Niels ^a   Carlsson, Leif G ^b   Dobrev, Dobromir ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; NEW DRUG; NILOTINIB; POTASSIUM CHANNEL HERG;

CARDIAC SAFETY ASSAY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CHANNEL GATING; DRUG APPROVAL; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; HEART MUSCLE CELL; HEART PROARRHYTHMIA; HUMAN; MATHEMATICAL MODEL; NONHUMAN; PATCH CLAMP TECHNIQUE; PLURIPOTENT STEM CELL; POTASSIUM CURRENT; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; TORSADE DES POINTES;

ANIMALS; DELAYED RECTIFIER POTASSIUM CHANNELS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; TORSADES DE POINTES;

EID: 84889820684     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.11.004     Document Type: Review

References (60)

1. J. Bowes, A.J. Brown, J. Hamon, W. Jarolimek, A. Sridhar, and G. Waldron Reducing safety-related drug attrition: the use of in vitro pharmacological profiling Nat Rev Drug Discov 11 2012 909 922
2. H. Laverty, C. Benson, E. Cartwright, M. Cross, C. Garland, and T. Hammond How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines Br J Pharmacol 163 2011 675 693
3. D. Rampe, and A.M. Brown A history of the role of the hERG channel in cardiac risk assessment J Pharmacol Toxicol Methods 68 2013 13 22
4. R.R. Shah Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter Br J Clin Pharmacol 75 2013 347 358
5. T. Meyer, P. Sartipy, F. Blind, C. Leisgen, and E. Guenther New cell models and assays in cardiac safety profiling Expert Opin Drug Metab Toxicol 3 2007 507 517 (Pubitemid 351324960)
6. S. Nattel, G. Duker, and L. Carlsson Model systems for the discovery and development of antiarrhythmic drugs Prog Biophys Mol Biol 98 2008 328 339
7. J.C. Hancox, M.J. McPate, A. El Harchi, and Y.H. Zhang The hERG potassium channel and hERG screening for drug-induced torsades de pointes Pharmacol Ther 119 2008 118 132
8. J. Hamdam, S. Sethu, T. Smith, A. Alfirevic, M. Alhaidari, and J. Atkinson Safety pharmacology - current and emerging concepts Toxicol Appl Pharmacol 2013 10.1016/j.taap.2013.04.039 Epub
9. W.A. Schmalhofer, A.M. Swensen, B.S. Thomas, J.P. Felix, R.J. Haedo, and K. Solly A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-a-go-go related gene potassium channel Assay Drug Dev Technol 8 2010 714 726
10. D.J. Gillie, S.J. Novick, B.T. Donovan, L.A. Payne, and C. Townsend Development of a high-throughput electrophysiological assay for the human ether-a-go-go related potassium channel hERG J Pharmacol Toxicol Methods 67 2013 33 44
11. P. Kannankeril, D.M. Roden, and D. Darbar Drug-induced long QT syndrome Pharmacol Rev 62 2010 760 781
12. L. Carlsson The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes Pharmacol Ther 119 2008 160 167
13. J. Heijman, N. Voigt, and D. Dobrev New directions in antiarrhythmic drug therapy for atrial fibrillation Future Cardiol 9 2013 71 88
14. D.M. Roden, and R.L. Abraham Refining repolarization reserve Heart Rhythm 8 2011 1756 1757
15. A. Varro, and I. Baczko Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk Br J Pharmacol 164 2011 14 36
16. J. Kramer, C.A. Obejero-Paz, G. Myatt, Y.A. Kuryshev, A. Bruening-Wright, and J.S. Verducci MICE models: superior to the HERG model in predicting Torsade de Pointes Sci Rep 3 2013 2100
17. G.R. Mirams, Y. Cui, A. Sher, M. Fink, J. Cooper, and B.M. Heath Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk Cardiovasc Res 91 2011 53 61
18. Ks blockade contributes importantly to drug-induced long QT syndrome Circ Arrhythm Electrophysiol 2013 10.1161/CIRCEP.113.000239 Epub
19. D.M. Johnson, M.M. de Jong, H.J. Crijns, L.G. Carlsson, and P.G. Volders Reduced ventricular proarrhythmic potential of the novel combined ion-channel blocker AZD1305 versus dofetilide in dogs with remodeled hearts Circ Arrhythm Electrophysiol 5 2012 201 209
20. Z. Lu, C.Y. Wu, Y.P. Jiang, L.M. Ballou, C. Clausen, and I.S. Cohen Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome Sci Transl Med 4 2012 131ra50
21. W. Chu, C. Li, X. Qu, D. Zhao, X. Wang, and X. Yu Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome Cardiovasc Res 96 2012 90 98
22. Ks and action potential repolarization Heart Rhythm 10 2013 1220 1228
23. A.T. Dennis, L. Wang, H. Wan, D. Nassal, I. Deschenes, and E. Ficker Molecular determinants of pentamidine-induced hERG trafficking inhibition Mol Pharmacol 81 2012 198 209
24. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, and S. Palethorpe Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc Res 58 2003 32 45 (Pubitemid 36351620)
25. Kr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects Circulation 91 1995 1799 1806
26. G.Y. Di Veroli, M.R. Davies, H. Zhang, N. Abi-Gerges, and M.R. Boyett High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment Am J Physiol Heart Circ Physiol 304 2013 H104 H117
27. G.Y. Di Veroli, M.R. Davies, H. Zhang, N. Abi-Gerges, and M.R. Boyett hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment J Cardiovasc Electrophysiol 2013 in press
28. H. Watanabe, T. Yang, D.M. Stroud, J.S. Lowe, L. Harris, and T.C. Atack Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro Circulation 124 2011 1001 1011
29. T. O'Hara, and Y. Rudy Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species Am J Physiol Heart Circ Physiol 302 2012 H1023 H1030
30. P. Ellinghaus, R.J. Scheubel, D. Dobrev, U. Ravens, J. Holtz, and J. Huetter Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays J Thorac Cardiovasc Surg 129 2005 1383 1390 (Pubitemid 40804859)
31. D. Dobrev, and S. Nattel New antiarrhythmic drugs for treatment of atrial fibrillation Lancet 375 2010 1212 1223
32. E.R. Behr, and D. Roden Drug-induced arrhythmia: pharmacogenomic prescribing Eur Heart J 34 2013 89 95
33. E.K. Heist, and J.N. Ruskin Drug-induced arrhythmia Circulation 122 2010 1426 1435
34. S. Kaab, D.C. Crawford, M.F. Sinner, E.R. Behr, P.J. Kannankeril, and A.A. Wilde A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes Circ Cardiovasc Genet 5 2012 91 99
35. Y. Jamshidi, I.M. Nolte, C. Dalageorgou, D. Zheng, T. Johnson, and R. Bastiaenen Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia J Am Coll Cardiol 60 2012 841 850
36. R. Varkevisser, S.C. Wijers, M.A. van der Heyden, J.D. Beekman, M. Meine, and M.A. Vos Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo Heart Rhythm 9 2012 1718 1726
37. P.J. Guns, D.M. Johnson, J. Van Op den Bosch, E. Weltens, and J. Lissens The electro-mechanical window in anaesthetized guinea pigs: a new marker in screening for Torsade de Pointes risk Br J Pharmacol 166 2012 689 701
38. T.H. Said, L.D. Wilson, D. Jeyaraj, A.A. Fossa, and D.S. Rosenbaum Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia J Cardiovasc Pharmacol 60 2012 165 171
39. A.J. Sauer, and C. Newton-Cheh Clinical and genetic determinants of torsade de pointes risk Circulation 125 2012 1684 1694
40. M. Hinterseer, B.M. Beckmann, M.B. Thomsen, A. Pfeufer, M. Ulbrich, and M.F. Sinner Usefulness of short-term variability of QT intervals as a predictor for electrical remodeling and proarrhythmia in patients with nonischemic heart failure Am J Cardiol 106 2010 216 220
41. M. Mercola, A. Colas, and E. Willems Induced pluripotent stem cells in cardiovascular drug discovery Circ Res 112 2013 534 548
42. K. Harris, M. Aylott, Y. Cui, J.B. Louttit, N.C. McMahon, and A. Sridhar Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays Toxicol Sci 134 2013 412 426
43. E.G. Navarrete, P. Liang, F. Lan, V. Sanchez-Freire, C.S. Simmons, and T. Gong Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays Circulation 128 2013 S3 S13
44. P. Liang, F. Lan, A.S. Lee, T. Gong, V. Sanchez-Freire, and Y. Wang Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity Circulation 127 2013 1677 1691
45. M.K. Jonsson, M.A. Vos, G.R. Mirams, G. Duker, P. Sartipy, and T.P. de Boer Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG J Mol Cell Cardiol 52 2012 998 1008
46. Y. Qu, B. Gao, M. Fang, and H.M. Vargas Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay J Pharmacol Toxicol Methods 68 2013 74 81
47. L.G. Valerio Jr., S. Balakrishnan, M.L. Fiszman, D. Kozeli, M. Li, and S. Moghaddam Development of cardiac safety translational tools for QT prolongation and torsade de pointes Expert Opin Drug Metab Toxicol 9 2013 801 815
48. J. Heijman, A. Zaza, D.M. Johnson, Y. Rudy, R.L. Peeters, and P.G. Volders Determinants of beat-to-beat variability of repolarization duration in the canine ventricular myocyte: a computational analysis PLoS Comput Biol 9 2013 e1003202
49. 2+ model: sinus rhythm and chronic atrial fibrillation Circ Res 109 2011 1055 1066
50. M.R. Davies, H.B. Mistry, L. Hussein, C.E. Pollard, J.P. Valentin, and J. Swinton An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment Am J Physiol Heart Circ Physiol 302 2012 H1466 H1480
51. N. Zemzemi, M.O. Bernabeu, J. Saiz, J. Cooper, P. Pathmanathan, and G.R. Mirams Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials Br J Pharmacol 168 2013 718 733
52. R.C. Elkins, M.R. Davies, S.J. Brough, D.J. Gavaghan, Y. Cui, and N. Abi-Gerges Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment J Pharmacol Toxicol Methods 68 2013 112 122
53. W.S. Redfern, G. Waldron, M.J. Winter, P. Butler, M. Holbrook, and R. Wallis Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring J Pharmacol Toxicol Methods 58 2008 110 117
54. R.T. Peterson, and C.A. Macrae Systematic approaches to toxicology in the zebrafish Annu Rev Pharmacol Toxicol 52 2012 433 453
55. A.O. Verkerk, and C.A. Remme Zebrafish: a novel research tool for cardiac (patho)electrophysiology and ion channel disorders Front Physiol 3 2012 255
56. G.H. Chaudhari, K.S. Chennubhotla, K. Chatti, and P. Kulkarni Optimization of the adult zebrafish ECG method for assessment of drug-induced QTc prolongation J Pharmacol Toxicol Methods 67 2013 115 120
57. M.K. Sabeh, H. Kekhia, and C.A. Macrae Optical mapping in the developing zebrafish heart Pediatr Cardiol 33 2012 916 922
58. P. Nemtsas, E. Wettwer, T. Christ, G. Weidinger, and U. Ravens Adult zebrafish heart as a model for human heart? An electrophysiological study J Mol Cell Cardiol 48 2010 161 171
59. D.J. Milan, T.A. Peterson, J.N. Ruskin, R.T. Peterson, and C.A. MacRae Drugs that induce repolarization abnormalities cause bradycardia in zebrafish Circulation 107 2003 1355 1358 (Pubitemid 36350731)
60. D. Dobrev, L. Carlsson, and S. Nattel Novel molecular targets for atrial fibrillation therapy Nat Rev Drug Discov 11 2012 275 291